BUY COMBO-MED (400 MG/ML – 10 ML)
MAIN PRODUCT DESCRIPTION
Product Overview & Pharmaceutical Specifications
Combo-Med 400 mg/ml is an injectable preparation containing two androgenic compounds: nandrolone decanoate and testosterone cypionate. According to the supplied product information, each stated formulation contains 200 mg of nandrolone decanoate and 200 mg of testosterone cypionate, providing a combined stated strength of 400 mg/ml.
Androgens are hormones and synthetic derivatives of testosterone that participate in the development and maintenance of male reproductive tissues and secondary sexual characteristics. The supplied information describes androgen activity in tissues including the prostate, seminal vesicles, penis and scrotum, as well as effects on hair distribution, the larynx, body musculature and fat distribution.
Product Specifications
- Product: Combo-Med
- Strength: 400 mg/ml
- Active Ingredient 1: Nandrolone decanoate – 200 mg
- Active Ingredient 2: Testosterone cypionate – 200 mg
- Total stated active content: 400 mg/ml
- Dosage Form: Injectable preparation
- Route: Injection
- Pack Size: 10 ml
- Drug Class: Anabolic/androgenic steroids
The supplied material does not provide molecular formulae, molecular weights, CAS numbers, manufacturer details or a verified regulatory authorisation for the specific Combo-Med presentation. These details have therefore not been added.
Pharmacological Class
Combo-Med belongs to the anabolic/androgenic steroid class. Nandrolone and testosterone are androgenic compounds that act through androgen receptors and can influence protein metabolism, reproductive tissues and other androgen-responsive organs.
The supplied source describes androgenic steroids as synthetic derivatives of testosterone and states that their biological actions include effects on nitrogen balance and protein metabolism.
Androgen Receptor Activity
Androgens exert many of their biological effects through the androgen receptor, an intracellular receptor that regulates gene expression in androgen-responsive tissues.
Testosterone and nandrolone can activate androgen-dependent signalling pathways. These pathways are associated with the development and maintenance of male reproductive characteristics and can also influence skeletal muscle and other tissues.
Because androgen receptors are distributed throughout the body, androgenic medicines can affect multiple organ systems. They should therefore not be regarded as substances acting solely on muscle tissue.
Protein and Nitrogen Metabolism
The supplied information states that androgens can increase protein anabolism and decrease protein catabolism. It also describes changes in nitrogen balance associated with androgenic steroid administration.
Nitrogen balance is influenced by multiple factors, including protein and calorie intake. The source specifically notes that improved nitrogen balance depends on adequate nutritional intake.
These pharmacological effects are part of the biological activity of androgenic steroids and should not be interpreted as a guarantee of a specific increase in muscle mass.
Nandrolone Decanoate
Nandrolone decanoate is an esterified androgenic compound belonging to the nandrolone family. The ester influences the release and persistence of nandrolone following administration.
The supplied product contains 200 mg of nandrolone decanoate as one of its two active components.
The source material does not provide sufficient Combo-Med-specific pharmacokinetic information to establish an absorption profile, elimination half-life or duration of activity for the combined formulation.
Testosterone Cypionate
Testosterone cypionate is an esterified form of testosterone designed for administration by injection. Once released from the ester, testosterone interacts with androgen receptors and is metabolised through normal steroid pathways.
The supplied product contains 200 mg of testosterone cypionate as the second active component.
Testosterone can also be converted to other metabolites, including dihydrotestosterone and estradiol, through naturally occurring enzymatic pathways. The supplied product information does not provide formulation-specific data allowing precise prediction of these processes following Combo-Med administration.
Clinical Context
The supplied information identifies anabolic/androgenic steroids as being used in certain medical contexts involving undernutrition or muscle wasting. It also mentions use in HIV-associated wasting.
These statements represent the supplied source material and should not be interpreted as confirmation that Combo-Med itself has been authorised for those indications.
No country-specific marketing authorisation, approved indication or official Summary of Product Characteristics has been supplied for this particular combination product.
Contraindications and Important Precautions
The supplied information states that androgen therapy should be avoided or carefully considered in certain medical circumstances, including:
- Male breast cancer
- Female breast cancer associated with elevated blood calcium
- Prostate cancer
- Kidney disease
- Severe liver disease
- Pregnancy
Androgen treatment may also influence blood glucose regulation. Patients with diabetes may require appropriate monitoring and adjustment of their diabetes medicines under medical supervision.
The source specifically advises caution in children because androgen treatment can affect skeletal development and sexual maturation. The supplied information states that androgenic treatment may stunt growth in individuals under 18 years of age.
Possible Adverse Effects
The supplied information reports a range of possible adverse effects, including:
- Diarrhoea
- Excitation
- Sleep disturbance
- Mood changes
- Swelling
- Rapid weight gain
- Acne
- Breathing difficulties
- Hair loss
- Impotence
- Breast swelling
- Changes in testicular size
- Painful or prolonged erection
- Headache
These effects can vary depending on the individual, exposure and underlying health conditions.
Androgenic steroid therapy can also affect metabolic and endocrine parameters. Appropriate monitoring should therefore be determined by a qualified healthcare professional.
Dosage and Administration
The supplied source provides a proposed schedule of administration twice weekly and gives a total weekly amount of 400–800 mg. Because Combo-Med contains two active androgenic substances and is presented as a prescription-type injectable preparation, these figures should not be interpreted as a general self-administration protocol.
The appropriate dose depends on the medical indication, patient characteristics, formulation and authorised prescribing information.
Patients should not independently increase the dose, frequency or duration of treatment.
Product Presentation
The supplied product presentation is:
Combo-Med 400 mg/ml – 10 ml injectable preparation.
Each stated formulation contains:
- 200 mg nandrolone decanoate
- 200 mg testosterone cypionate
Storage
The supplied source states:
Store in a cool, dry place. Protect from light.
No specific temperature range was supplied.
Regulatory and Pharmaceutical Information
The supplied material does not provide verified regulatory authorisation for Combo-Med in the EU or any individual European country.
Accordingly, no claim is made that this specific combination is EU-authorised, prescription-only in every EU Member State or legally saleable throughout Europe.
The product should be described according to its documented composition and formulation rather than assumptions about regulatory status.
Important Pharmaceutical Disclaimer
Combo-Med contains pharmacologically active anabolic/androgenic steroids. The information provided is based on the supplied product material and does not replace official prescribing information or professional medical advice.
Patients should consult a qualified healthcare professional before treatment, particularly where cardiovascular, hepatic, renal, endocrine or reproductive conditions are present.
